# Phase II Trial of RC1416 Injection in Asthma

> **NCT07403487** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Nanjing RegeneCore Biotech Co., Ltd.** · enrollment: 195 (estimated)

## Conditions studied

- Moderate to Severe Asthma

## Interventions

- **DRUG:** RC1416
- **DRUG:** RC1416 Placebo

## Key facts

- **NCT ID:** NCT07403487
- **Lead sponsor:** Nanjing RegeneCore Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2027-10-25
- **Final completion:** 2028-02-28
- **Target enrollment:** 195 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07403487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07403487, "Phase II Trial of RC1416 Injection in Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07403487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*